Nov 20, 2023 7:00am EST ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
Nov 14, 2023 4:30pm EST ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
Sep 06, 2023 12:18pm EDT ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 14, 2023 5:33pm EDT ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
Jul 17, 2023 7:00am EDT ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline
Jun 30, 2023 8:00am EDT ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved